vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $334.0M, roughly 1.8× WYNDHAM HOTELS & RESORTS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -18.0%, a 58.8% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -76.3%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $168.0M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -4.6%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
EXEL vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $334.0M |
| Net Profit | $244.5M | $-60.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | — |
| Net Margin | 40.8% | -18.0% |
| Revenue YoY | 5.6% | -76.3% |
| Net Profit YoY | 74.8% | -170.6% |
| EPS (diluted) | $0.89 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $334.0M | ||
| Q4 25 | $597.8M | $334.0M | ||
| Q3 25 | $568.3M | $382.0M | ||
| Q2 25 | $555.4M | $397.0M | ||
| Q1 25 | $566.8M | $316.0M | ||
| Q4 24 | — | $336.0M | ||
| Q3 24 | $539.5M | $396.0M | ||
| Q2 24 | $637.2M | $367.0M |
| Q1 26 | $244.5M | $-60.0M | ||
| Q4 25 | $193.6M | $-60.0M | ||
| Q3 25 | $184.8M | $105.0M | ||
| Q2 25 | $159.6M | $87.0M | ||
| Q1 25 | $139.9M | $61.0M | ||
| Q4 24 | — | $85.0M | ||
| Q3 24 | $118.0M | $102.0M | ||
| Q2 24 | $226.1M | $86.0M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -11.4% | ||
| Q3 25 | 37.6% | 46.6% | ||
| Q2 25 | 33.6% | 37.8% | ||
| Q1 25 | 28.8% | 35.4% | ||
| Q4 24 | — | 38.4% | ||
| Q3 24 | 25.2% | 43.2% | ||
| Q2 24 | 43.3% | 39.5% |
| Q1 26 | 40.8% | -18.0% | ||
| Q4 25 | 32.4% | -18.0% | ||
| Q3 25 | 32.5% | 27.5% | ||
| Q2 25 | 28.7% | 21.9% | ||
| Q1 25 | 24.7% | 19.3% | ||
| Q4 24 | — | 25.3% | ||
| Q3 24 | 21.9% | 25.8% | ||
| Q2 24 | 35.5% | 23.4% |
| Q1 26 | $0.89 | $-0.80 | ||
| Q4 25 | $0.69 | $-0.77 | ||
| Q3 25 | $0.65 | $1.36 | ||
| Q2 25 | $0.55 | $1.13 | ||
| Q1 25 | $0.47 | $0.78 | ||
| Q4 24 | — | $1.06 | ||
| Q3 24 | $0.40 | $1.29 | ||
| Q2 24 | $0.77 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $468.0M |
| Total Assets | $2.8B | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $64.0M | ||
| Q4 25 | $988.5M | $64.0M | ||
| Q3 25 | $791.1M | $70.0M | ||
| Q2 25 | $1.0B | $50.0M | ||
| Q1 25 | $1.1B | $48.0M | ||
| Q4 24 | — | $103.0M | ||
| Q3 24 | $1.2B | $72.0M | ||
| Q2 24 | $1.0B | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | $2.2B | $468.0M | ||
| Q4 25 | $2.2B | $468.0M | ||
| Q3 25 | $2.0B | $583.0M | ||
| Q2 25 | $2.1B | $570.0M | ||
| Q1 25 | $2.2B | $579.0M | ||
| Q4 24 | — | $650.0M | ||
| Q3 24 | $2.3B | $583.0M | ||
| Q2 24 | $2.1B | $623.0M |
| Q1 26 | $2.8B | $4.2B | ||
| Q4 25 | $2.8B | $4.2B | ||
| Q3 25 | $2.7B | $4.3B | ||
| Q2 25 | $2.8B | $4.3B | ||
| Q1 25 | $2.9B | $4.2B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | $3.0B | $4.2B | ||
| Q2 24 | $2.8B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $367.0M |
| Free Cash FlowOCF − Capex | $332.4M | $168.0M |
| FCF MarginFCF / Revenue | 55.5% | 50.3% |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | $367.0M | ||
| Q4 25 | $290.3M | $152.0M | ||
| Q3 25 | $49.0M | $86.0M | ||
| Q2 25 | $211.4M | $70.0M | ||
| Q1 25 | $240.3M | $59.0M | ||
| Q4 24 | — | $134.0M | ||
| Q3 24 | $271.3M | $79.0M | ||
| Q2 24 | $119.5M | $1.0M |
| Q1 26 | $332.4M | $168.0M | ||
| Q4 25 | $288.8M | $136.0M | ||
| Q3 25 | $46.2M | $75.0M | ||
| Q2 25 | $208.5M | $58.0M | ||
| Q1 25 | $236.3M | $52.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | $263.1M | $71.0M | ||
| Q2 24 | $113.0M | $-6.0M |
| Q1 26 | 55.5% | 50.3% | ||
| Q4 25 | 48.3% | 40.7% | ||
| Q3 25 | 8.1% | 19.6% | ||
| Q2 25 | 37.5% | 14.6% | ||
| Q1 25 | 41.7% | 16.5% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | 48.8% | 17.9% | ||
| Q2 24 | 17.7% | -1.6% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 4.8% | ||
| Q3 25 | 0.5% | 2.9% | ||
| Q2 25 | 0.5% | 3.0% | ||
| Q1 25 | 0.7% | 2.2% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | 1.5% | 2.0% | ||
| Q2 24 | 1.0% | 1.9% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | 0.82× | ||
| Q2 25 | 1.32× | 0.80× | ||
| Q1 25 | 1.72× | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | 2.30× | 0.77× | ||
| Q2 24 | 0.53× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
